NCT00708071已完成2 期
An Exploratory Phase 2 Clinical Study to Evaluate Efficacy and Safety of the Adjuvant Use of Fibrin Sealant With 4 IU/mL Thrombin, Vapor Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) in Subjects Undergoing Rhytidectomy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
- 试验地点
- 6
- 主要终点
- Visual Comparison of Ecchymosis at Postoperative Day 3
研究概览
简要总结
The primary objective of this study is to evaluate the efficacy and safety of fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated (FS VH S/D 4) when used to reduce early postoperative bruising in participants undergoing a rhytidectomy (face-lift).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects planned for facial rhytidectomy
- •Subjects who read, understand and sign the written informed consent
- •Healthy female or male subjects as determined by the investigator using standard pre-operative assessments to include laboratory tests and ECG
- •Subjects 18-75 years old, inclusively
- •Subjects who are able and willing to comply with the protocol requirements
- •Female subjects of childbearing potential with a negative urine or serum pregnancy test within 72 hours of surgery
排除标准
- •Pregnant or lactating women
- •Subjects who have undergone previous face-lift surgery
- •Subjects undergoing abbreviated face-lift procedures such as deep plane procedures, minimal undermining procedures, thread lifts, and minimal access cranial suspension
- •Subjects indicated for concurrent facial surgeries during the operation (e.g. forehead plasty, blepharoplasty, rhinoplasty, buccal fat removal, any filler injections including fat injections, lip augmentation, skin resurfacing procedures etc.)
- •Subjects indicated for additional procedures during the same operation (e.g., liposuction, mastoplasty etc.)
- •Subjects who had prior silicone injections to their face (Botox and/or Restylane are allowed)
- •Subjects considered by the investigator to be smokers
- •Subjects with ecchymosis and/or edema on the face on day 0, prior to surgery
- •Subjects with known (documented) bleeding or coagulation disorders
- •Subjects currently being treated with anti-coagulants
- •Subjects treated with Aspirin in the last 7 days or use of other Non-steroidal anti-inflammatory drug (NSAIDs) within the last 7 days prior to surgery
- •Subjects with vascular disorders, cardiovascular disease, and/or uncontrolled hypertension
- •Subjects with diabetes mellitus
- •Subjects with a history of Bell´s palsy
- •Subjects with connective tissue disorders
- •Subjects with documented history of pathologically or pharmacologically induced immune deficiency
- •Subjects receiving systemic corticosteroid treatment for a chronic condition within 2 to 30 days prior to the surgery
- •Subjects with a known sensitivity to fibrin sealants
- •Subjects with a known psychiatric disorder (e.g., depression, obsessive compulsive disorder, anxiety, eating disorders, etc)
- •Subjects who have participated in another clinical study within 30 days prior to this study
结局指标
主要结局
Visual Comparison of Ecchymosis at Postoperative Day 3
时间窗: Through Postoperative Day 3
Comparison between the FS VH S/D 4 treated side of the face and the side treated using standard of care (SoC) assessed by 5 separate blinded reviewers using standard digital photographs.
Incidence of Adverse Events (AEs) Related to Study Product (FS VH S/D 4) Throughout the Study Period
时间窗: Through Postoperative Day 14 (± 1)
次要结局
- Visual Comparison of Ecchymosis at Day 1(Through Postoperative Day 1)
- Visual Comparison of Ecchymosis at Day 5(Through Postoperative Day 5)
- Visual Comparison of Ecchymosis at Day 7(Through Postoperative Day 7)
- Visual Comparison of Ecchymosis at Day 10(Through Postoperative Day 10)
- Visual Comparison of Ecchymosis at Day 14(Through Postoperative Day 14)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by 5 Independent, Blinded Reviewers- Day 1(Through Postoperative Day 1)
- Differences From Day 0 in Two-Point Discrimination Tests Days 3, 7, 10, 14(Postoperative Days 3, 7, 10, and 14)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by 5 Independent, Blinded Reviewers- Day 3(Through Postoperative Day 3)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by 5 Independent, Blinded Reviewers- Day 5(Through Postoperative Day 5)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by 5 Independent, Blinded Reviewers- Day 7(Through Postoperative Day 7)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by 5 Independent, Blinded Reviewers- Day 10(Through Postoperative Day 10)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by 5 Independent, Blinded Reviewers- Day 14(Through Postoperative Day 14)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by a Blinded On-site Evaluator-Day 3(Postoperative Day 3)
- Difference in Marchac Grades of Edema Between Two Sides of Face Assessed by Investigator Day 1(Through Postoperative Day 1)
- Difference in Marchac Grades of Edema Between Two Sides of Face Assessed by Investigator Day 3(Through Postoperative Day 3)
- Difference in Marchac Grades of Edema Between Two Sides of Face Assessed by Investigator Day 5(Through Postoperative Day 5)
- Difference in Marchac Grades of Edema Between Two Sides of Face Assessed by Investigator Day 7(Through Postoperative Day 7)
- Difference in Marchac Grades of Edema Between Two Sides of Face Assessed by Investigator Day 10(Through Postoperative Day 10)
- Difference in Marchac Grades of Edema Between Two Sides of Face Assessed by Investigator Day 14(Through Postoperative Day 14)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by Investigator- Day 1(Through Postoperative Day 1)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by Investigator- Day 3(Through Postoperative Day 3)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by Investigator- Day 5(Through Postoperative Day 5)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by Investigator- Day 7(Through Postoperative Day 7)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by Investigator- Day 10(Through Postoperative Day 10)
- Difference in Marchac Grades Using A Modified Marchac Scale (MMS) of Ecchymosis Between Two Sides of Face Assessed by Investigator- Day 14(Through Postoperative Day 14)
- Resolution of Ecchymosis as Assessed by Investigators(Postoperative Days 1, 3, 5, 7, 10, and 14)
- Resolution of Edema as Assessed by Investigators.(Postoperative Days 1, 3, 5, 7, 10, and 14)
- Total Volume of Drainage on Each Side of the Face(24 hours postoperative)
- Participants With Hematoma/Seroma(Days 0, 1, 3, 5, 7,10, and 14)
- Participants With Hematoma/Seroma During the Study(Through Postoperative Day 14 (± 1))
- Differences in Subjects' Assessments of Pain for Each Side of Face (SoC and FS VH S/D 4)(Days 1, 3, 5, 7,10, and 14)
- Differences in Subjects' Assessments of Numbness for Each Side of Face (SoC and FS VH S/D 4)(Days 1, 3, 5, 7,10, and 14)
- Participants' Assessment of Side of Face Preference (SoC and FS VH S/D 4)(Postoperative Days 1, 3, 5, 7, 10, and 14)
研究者
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
3 期
Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage (PLACE030)Esophageal Anastomotic LeakNCT03847857Sun Yat-sen University360
已完成
3 期
Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular SurgeryVascular Surgical BleedingNCT01662856Instituto Grifols, S.A.225
已完成
不适用
Evaluating the Use of Fibrin Tissue Adhesive in Melanoma PatientsMelanomaNCT00506311M.D. Anderson Cancer Center53
已完成
3 期
The Fibrin Pad Liver StudyHemorrhageNCT01166243Ethicon, Inc.84
已完成
不适用
Fibrin Melanoma Axillary Node Study in Patients With MelanomaMelanomaNCT00504582M.D. Anderson Cancer Center121